Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)
Safety Assessment of Cumulative Dose of Combivent® HFA-propelled Metered Dose Inhaler in Comparison to Combivent® CFC-propelled Metered Dose Inhaler. A Randomised, Double-blind, Active-controlled, Two-way Cross-over Study in COPD Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients 40 years of age or older
- A diagnosis of COPD as defined by American Thoracic Society (ATS) criteria. Patients must have relatively stable, moderate to severe airway obstruction with a baseline FEV 1 <=65% of predicted normal and FEV1/FVC >=70%.
- A smoking history of more than ten pack-years. A pack-year is defined as the equivalent of smoking one pack of 20 cigarettes per day for a year
- Able to perform technical satisfactory pulmonary function test
- Able to be trained in the proper use of a MDI
- Having signed an informed consent from prior to participation in the trial
- Affiliation to the French social security system or beneficiary of such a system
Exclusion Criteria:
- Significant disease other than COPD. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study
- Clinical relevant abnormal baseline hematology, blood chemistry or urinalysis. If the abnormality defines a disease listed as an exclusion criterion, the patient is excluded
- Serum glutamic oxaloacetic transaminase (SGOT) >80 IU/L; serum glutamic pyruvic transaminase (SGPT) >80IU/L, bilirubin >2.0mg/dL or creatinine >2.0mg/dL
- Serum potassium level above or below the normal range
- Total blood eosinophil count >=600/mm³
- Recent history (i.e., one year or less) of myocardial infarction
- Recent history (i.e., three years or less) of heart failure or any cardiac arrhythmia requiring drug therapy
- History of cancer, other than treated basal cell carcinoma, within the last five years
- History of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis
- History of thoracotomy with pulmonary resection. History or a thoracotomy for other reasons should be evaluated as per exclusion criteria no. 1
- History of asthma, allergic rhinitis or atopy
- History of or active alcohol or drug abuse
- Known active tuberculosis
- Upper respiratory tract infection or COPD exacerbation in the six weeks prior to screening visit or between the screening visit and visit 2
- Known symptomatic prostatic hypertrophy or bladder neck obstruction
- Known narrow-angle glaucoma
- Current significant psychiatric disorders
- Regular use of daytime oxygen therapy
- Use of beta-blocker medications, mono-amine oxidase inhibitors or tricyclic antidepressants
- Use of cromolyn sodium or nedocromil sodium
- Use of antihistamines.
- Use of oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose before screening visit or a change between the screening visit and visit2) or at a dose in excess of the equivalent of 10 mg of prednisone per day or 20mg every other day
- Use of oral beta-adrenergics or long-acting beta-adrenergics such as salmeterol (Serevent®) and formoterol in the two weeks prior to the screening visit or between the screening visit and visit 2
- Changes in the therapeutic plan within the last six weeks prior to the screening visit or between the screening visit and visit 2, excluding changes from long acting or oral beta-adrenergics to short acting inhaled beta-adrenergics for purposes of this trial
- Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception
- Known hypersensitivity to anti-cholinergic or beta-agonist drugs or any other component of either Combivent® formulations
- Use of an investigational drug within one month or six half lives prior to the screening visit
- Previous participation in this study
- Patient deprived of their freedom by a judicial or administrative decision
- Patient leaving in medical or social establishments
- Patient hospitalized for mental disorder without his (her) consent
- Patient under guardianship
- Patient in emergency situations
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Combivent® HFA
|
|
|
Active Comparator: Combivent® CFC
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of patients with clinically significant changes in electrocardiogram (ECG) parameters (ventricular rate, PQ, QRS, QT and QTc intervals)
Time Frame: Baseline, up to 8 days after last treatment day
|
Baseline, up to 8 days after last treatment day
|
|
Number of patients with clinically significant changes in vital signs (blood pressure, puls rate, respiratory rate)
Time Frame: Baseline, up to 8 days after last treatment day
|
Baseline, up to 8 days after last treatment day
|
|
Changes in intra ocular pressure (IOP)
Time Frame: Baseline, up to 30 min after last drug administration
|
Baseline, up to 30 min after last drug administration
|
|
Changes in serum potassium levels
Time Frame: Baseline, up to 180 min after last drug administration
|
Baseline, up to 180 min after last drug administration
|
|
Changes in serum glucose levels
Time Frame: Baseline, up to 60 min after last drug administration
|
Baseline, up to 60 min after last drug administration
|
|
Number of patients with clinically significant changes from baseline in clinical laboratory evaluations
Time Frame: Baseline, 8 days after last treatment day
|
Baseline, 8 days after last treatment day
|
|
Number of patients with adverse events including paradoxical bronchospasm
Time Frame: Up to 8 days after last treatment day
|
Up to 8 days after last treatment day
|
|
Number of patients with clinically significant changes from baseline in physical examination
Time Frame: Baseline, 8 days after last treatment day
|
Baseline, 8 days after last treatment day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in FEV1 (forced expiratory volume in one second)
Time Frame: Baseline, up to 180 min after last drug administration
|
Baseline, up to 180 min after last drug administration
|
|
Change in FVC (forced vital capacity)
Time Frame: Baseline, up to 180 min after last drug administration
|
Baseline, up to 180 min after last drug administration
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1012.43
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
NCT03745547CompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary Disease
-
NCT05431218CompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease Severe
-
NCT05539547Not yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
NCT06629675RecruitingChronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Lung Disease | Chronic Obstructive Airway Disease
-
NCT04828837TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With Exacerbation
-
NCT03573817CompletedChronic Obstructive Pulmonary Disease (COPD)
-
NCT01260389CompletedChronic Obstructive Pulmonary Disease (COPD)
-
NCT04285047UnknownChronic Obstructive Pulmonary Disease (13645005)
-
NCT03644836CompletedBroncho Chronic Obstructive Pulmonary Disease
-
NCT02238483CompletedChronic Obstructive Pulmonary Disease COPD
Clinical Trials on Combivent® HFA inhalation aerosol
-
NCT02182674CompletedPulmonary Disease, Chronic Obstructive
-
NCT02194205TerminatedPulmonary Disease, Chronic Obstructive
-
NCT01537692Completed
-
NCT01188577CompletedAsthma | Shortness of Breath | Wheezing | Bronchospasm
-
NCT07633314Not yet recruiting
-
NCT05025215Recruiting
-
NCT06916273Completed
-
NCT02150499Terminated
-
NCT06294756CompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 Syndrome